STMs, such as carcinoembryonic antigen (CEA), are routinely employed for NSCLC screening and recurrence evaluation and have been linked to prognostic variables such as a higher TNM stage [31]. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.